PRMT5 is overexpressed or hyperactive in a number of tumor types and promotes tumor progression, including breast cancer, acute myeloid leukemia, lung, ovarian, glioblastoma, and prostate cancer [14,15,16,17,18,19,20,21]. Here, PRMT5 is linked to neoplasm.